{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:18:18Z","timestamp":1790986698759,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,3,24]],"date-time":"2004-03-24T00:00:00Z","timestamp":1080086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>It has been shown that adoptive immunotherapy with Epstein\u2013Barr virus (EBV)\u2010specific cytotoxic T\u2010lymphocytes (CTL) is effective for the treatment of EBV\u2010induced lymphoproliferative disease in stem cell transplantation recipients and organ transplantation recipients. The role of EBV CTL in other tumors for which this virus has been implicated in pathogenesis, such as EBV\u2010positive Hodgkin disease (HD), has not been demonstrated clearly.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To investigate the antitumor effects and toxicity of allogeneic EBV CTL in EBV\u2010positive HD, the authors initiated a pilot trial in which EBV CTL were cultured from allogeneic, partially human leukocyte antigen\u2010matched donors and were infused into patients who had therapy\u2010refractory disease. The first cohort of 3 patients (Cohort I) received 3 separate infusions of EBV CTL (5.0 \u00d7 10<jats:sup>6<\/jats:sup> EBV CTL\/kg per dose), and the second cohort (Cohort II) received 30 mg\/m<jats:sup>2<\/jats:sup> per day of fludarabine for 3 days followed by a single CTL infusion (1.5 \u00d7 10<jats:sup>7<\/jats:sup> EBV CTL\/kg).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>All three patients in Cohort I had decreases in measurable disease after EBV CTL infusions, and one of those patients was without evidence of disease 22 months after infusion. Two of 3 patients in Cohort II had decreases in measurable disease, although it was not determined whether those decreases were related to fludarabine or to CTL, and 1 patient in Cohort II had 7 months without disease progression. Unlike the patients in Cohort I, fludarabine recipients did not have increases in antidonor CTL responses. Donor cells could not be detected in any of the CTL recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Adoptive immunotherapy with allogeneic EBV CTL was safe for patients with recurrent, refractory, EBV\u2010positive HD; and clinical responses may be observed without the establishment of detectable donor lymphoid chimerism. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20188","type":"journal-article","created":{"date-parts":[[2004,4,15]],"date-time":"2004-04-15T19:05:50Z","timestamp":1082055950000},"page":"1892-1901","source":"Crossref","is-referenced-by-count":60,"title":["Adoptive immunotherapy with allogeneic Epstein\u2013Barr virus (EBV)\u2010specific cytotoxic T\u2010lymphocytes for recurrent, EBV\u2010positive Hodgkin disease"],"prefix":"10.1002","volume":"100","author":[{"given":"Kenneth G.","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,3,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058399"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.5.1381.bloodjournal8551381"},{"key":"e_1_2_6_4_2","first-page":"86","article-title":"Epstein\u2013Barr viral DNA in tissues of Hodgkin's disease","volume":"129","author":"Weiss LM","year":"1987","journal-title":"Am J Pathol."},{"key":"e_1_2_6_5_2","first-page":"1259","article-title":"Epstein\u2013Barr virus and Hodgkin's disease: correlative in situ hybridization and polymerase chain reaction study","volume":"139","author":"Weiss LM","year":"1991","journal-title":"Am J Pathol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5913.253"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903163201103"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-364933-1.50012-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1990.tb02561.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(72)90008-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197401242900402"},{"key":"e_1_2_6_12_2","first-page":"673","article-title":"The impact of Hodgkin's disease on the immune system","volume":"17","author":"Slivnick DJ","year":"1990","journal-title":"Semin Oncol."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555818289.ch4"},{"key":"e_1_2_6_14_2","first-page":"4216","article-title":"Long\u2010term T\u2010cell\u2010mediated immunity to Epstein\u2013Barr virus","volume":"41","author":"Rickinson AB","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830121206"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.1.157"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/mp.53.5.262"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V89.6.1978","article-title":"Isolation of Epstein Barr virus (EBV)\u2010specific cytotoxic T lymphocytes that lyse Reed\u2013Sternberg cells: implications for immune\u2010mediated therapy of EBV+ Hodgkin's disease","volume":"89","author":"Sing AP","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404283301703"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91150-2"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2592"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199706150-00027"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200110270-00012"},{"key":"e_1_2_6_24_2","first-page":"6219","article-title":"Epstein\u2013Barr virus\u2010specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T\u2010cell based therapy","volume":"61","author":"Chapman ALN","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein\u2013Barr virus (EBV)\u2010specific cytotoxic T lymphocytes for the treatment of patients with EBV\u2010positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow MA","year":"1998","journal-title":"Blood."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03683.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119822"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0099"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880243"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200107000-00011"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65424-7"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.12.1939"},{"key":"e_1_2_6_33_2","first-page":"652a","article-title":"Large scale ex vivo expansion of antigen\u2010specific T cells engineered for activation\u2010dependent expression of transgene introduced by lentiviral vector mediated transduction","volume":"100","author":"Sun Q","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3179"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2594.bloodjournal8762594"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.158.7.3325","article-title":"Conserved CTL epitopes within EBV latent membrane protein 2. A potential target for CTL\u2010based therapy","volume":"158","author":"Lee SP","year":"1997","journal-title":"J Immunol."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200103)31:3<947::AID-IMMU947>3.0.CO;2-M"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1396"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80856-9"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.1.183"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242600099"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:49:03Z","timestamp":1760266143000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,24]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1002\/cncr.20188"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20188","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,24]]}}}